# Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/long-term-cost-effectiveness-of-oral-semaglutide-versus-empagliflozin-and/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Björn Eliasson,Åsa Ericsson,Adam Fridhammar,Andreas Nilsson,Sofie Persson,Barrie Chubb |
| Citations | 11 |
| DOI | 10.1007/s41669-021-00317-z |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://link.springer.com/content/pdf/10.1007/s41669-021-00317-z.pdf |
| OpenAlex ID | https://openalex.org/W4206988433 |
| PMID | 35064550 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Andreas Nilsson](https://scholariq.org/researchers/andreas-nilsson/)

## Paper journal

- [PharmacoEconomics - Open](https://scholariq.org/journals/pharmacoeconomics-open/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.